Form 4: Merck Director Christine E. Seidman Reports Acquisition of Phantom Stock Units

Merck & Co. director Christine E. Seidman acquired phantom stock units equivalent to 81.6747 shares of common stock on December 31, 2024.

Summary

• Christine E. Seidman, a director at Merck & Co., reported a transaction involving phantom stock units.
• On December 31, 2024, Ms. Seidman acquired phantom stock units equivalent to 81.6747 shares of Merck common stock.
• These phantom stock units will be settled in cash upon Ms. Seidman's termination of service, according to a pre-selected distribution schedule.
• The price of the underlying common stock at the time of the transaction was $99.48 per share.
• Ms. Seidman's holdings include shares acquired through dividend reinvestment transactions.
• Following the transaction, Ms. Seidman's total holdings of phantom stock units is 15,164.7394.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation, which is neither positive nor negative for the company's overall performance. The sentiment is neutral to slightly positive as it indicates alignment of director interests with the company's performance.

Future Outlook

The phantom stock units will be settled in cash upon Ms. Seidman's termination of service, according to a pre-selected distribution schedule.

Industry Context

This is a routine filing related to director compensation and is common practice for publicly traded companies.

Comparison to Industry Standards

• The use of phantom stock units as part of director compensation is a common practice among large publicly traded companies, including those in the pharmaceutical sector.
• Companies like Pfizer (PFE) and Johnson & Johnson (JNJ) also utilize similar equity-based compensation plans for their directors.
• The specific terms of these plans, such as vesting schedules and settlement methods, can vary, but the general concept of aligning director interests with shareholder value through equity-based awards is consistent across the industry.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns director interests with the company's performance.

Key Dates

Keywords

phantom stock, director, insider trading, Form 4, Merck, MRK, equity compensation